Inovio Pharmaceuticals, Inc. (INO) Income Statement

Revenue appears in only a handful of the ten reported quarters, and where it does, the amounts are in the tens to low hundreds of thousands of dollars, which is immaterial relative to the roughly $10M to $23M of quarterly R&D spending. The irregular pattern suggests the top line is driven by intermittent collaboration or licensing receipts rather than recurring commercial sales. Investors should treat the revenue line as non-representative of the underlying business until a predictable revenue source is identified.

Where revenue is reported, cost of goods sold has frequently been comparable to or larger than the revenue base, producing negative gross margins such as -7.2% and -5.6% in 2024. This pattern suggests the cost base is largely fixed and not yet tied to scaled product sales, so pricing power relative to peers cannot be meaningfully assessed. Margin analysis should be deferred until revenue reaches a level where gross profit is consistently measurable.

Operating expenses are almost entirely R&D and SG&A, and with negligible gross profit there is no operating leverage, since losses scale with spending rather than sales. The most recent quarter shows R&D falling to $10.8M, which may indicate spending discipline but does not yet demonstrate a path to breakeven. Investors should monitor whether R&D reductions reflect program prioritization or a slowdown in pipeline advancement.

The cost structure is heavily weighted toward clinical development, which is typical for a clinical-stage biotechnology company but leaves little room for margin improvement without commercial revenue. The decline in R&D from its 2024 peak may reflect program completions or cost reductions, though the reported data alone cannot confirm which. Management's expense discipline is best judged by whether SG&A stays flat as R&D is reduced, which it broadly has.